Compare Commvault Systems Inc (CVLT) vs Summit Therapeutics Inc (SMMT) Price & Performance

Commvault Systems (CVLT) trades at $151.00, up 0.48% on the day, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.42 surpassing the $1.16 estimate. The company maintains robust profitability metrics, including an 81.09% gross margin and 32.77% ROE, though valuation ratios like a P/E of 96.73 appear elevated. Positive news includes AWS competency achievements and new board appointments, reinforcing its market position.

The outlook remains favorable given earnings momentum and institutional confidence, but high valuation multiples pose a risk if growth moderates. Revenue is projected to rise to $1.2 billion in 2026, though net margin may compress. With no sell ratings and a consensus price target of $156.55, upside potential exists, but investors should monitor competitive pressures and execution on guidance.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.